BE882414A - NOVEL 4-AMINO-3-QUINOLEINE-CARBOXYLIC ACIDS AND ESTERS, ESPECIALLY USEFUL AS ANTISECRETORY AND ANTI-ULCER AGENTS - Google Patents

NOVEL 4-AMINO-3-QUINOLEINE-CARBOXYLIC ACIDS AND ESTERS, ESPECIALLY USEFUL AS ANTISECRETORY AND ANTI-ULCER AGENTS Download PDF

Info

Publication number
BE882414A
BE882414A BE0/199934A BE199934A BE882414A BE 882414 A BE882414 A BE 882414A BE 0/199934 A BE0/199934 A BE 0/199934A BE 199934 A BE199934 A BE 199934A BE 882414 A BE882414 A BE 882414A
Authority
BE
Belgium
Prior art keywords
emi
esters
quinoleine
antisecretory
amino
Prior art date
Application number
BE0/199934A
Other languages
French (fr)
Inventor
H R Munson
R S Alphin
Original Assignee
Robins Co Inc A H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robins Co Inc A H filed Critical Robins Co Inc A H
Publication of BE882414A publication Critical patent/BE882414A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Description

       

  La présente invention concerne certains acides et

  
 <EMI ID=1.1> 

  
d'Amérique n' 3 470 186 et dans J. Med. Chem. 1969, 12(6), pages 1096-
1097.

  
 <EMI ID=2.1> 

  
Les composés utiles selon l'invention pour inhiber

  
la sécrétion de l'acide chlorhydrique et traiter les ulcères peptiques

  
 <EMI ID=3.1> 

  

 <EMI ID=4.1> 


  
 <EMI ID=5.1>   <EMI ID=6.1> 

  
par la nourriture a également été réduit.

  
L'invention a donc pour objet une nouvelle méthode

  
 <EMI ID=7.1> 

  
l'invention pour diverses voies d'administration. 

  
D'autres objets et.avantages de l'invention appa-

  
 <EMI ID=8.1> 

  
l'équation suivante

  

 <EMI ID=9.1> 


  
 <EMI ID=10.1> 

  
un groupe alkyle inférieur.

  
On prépare les composés de formule II par chlorura-

  
 <EMI ID=11.1> 

  
tion réactionnelle est la suivante

  

 <EMI ID=12.1> 


  
 <EMI ID=13.1> 

  
groupe alkyle inférieur. 

  
On prépare les composés de formule III dans laquelle

  
 <EMI ID=14.1> 

  
pages 1204-1208. La réaction est représentée par l'équation suivante :

  

 <EMI ID=15.1> 


  
 <EMI ID=16.1> 

  
lyse et on peut préparer d'autres esters de l'invention par des techniques habituelles de réeetérification.

  
 <EMI ID=17.1> 

  
formule générale

  

 <EMI ID=18.1> 


  
 <EMI ID=19.1>   <EMI ID=20.1> 

  
rieur, (alkyl inférieur)alcoxy inférieur ou allyle, et leurs sels d'addition d'acides acceptables an pharmacie.

  
Par exemple, on a trouvé que l'effet du chlorhydrate

  
 <EMI ID=21.1>  

  
 <EMI ID=22.1> 

  
On décrit ci-après la synthèse utilisée pour préparer les composés 4-chloro de formule II qui sont les produits de ' départ utilisés pour la préparation des composés da formule 1. Préparation 1

  
 <EMI ID=23.1> 

  
d'oxychlorure de phosphore jusqu'à ce que tout le solide se soit dissous, et on chauffe ensuite au reflux pendant 2 h. Après refroidissement au-dessous de 100[deg.]C, on concentre le mélange dans un évapora teur rotatif. On dissout l'huile résiduelle dans 100 ml d'acétone

  
et on verse la solution sur 800 ml d'un mélange glace-eau. On neutra-

  
 <EMI ID=24.1> 

  
solide successivement par 450 ml, 250 ml et 100 ml de chlorure de méthylène. On réunit les extraits, on lave à l'eau, on sèche sur

  
 <EMI ID=25.1> 

  
d'une huile qui cristallise au refroidissement en un solide blanc sale. F. 75-77*C.

  

 <EMI ID=26.1> 
 

  
Ce qui précède cet une description générale de la préparation des *@tort de l'invention. Les exemples 1 et 2 ci-après illustrent d'une manière générale la préparation des esters. Les

  
 <EMI ID=27.1> 

  
d'acides est illustrée dans les exemples 72 et 73, où l'ester est hydrolysé en acide. Les sels métalliques des acides, tels que les sels de métaux alcalins, peuvent aussi être préparés par les méthodes habituelles de réaction avec une base de métal alcalin et isolement des tels. Les exemples 85 à 88 illustrent encore la conversion des

  
 <EMI ID=28.1> 

  
Les exemples suivants illustrent l'invention sans toutefois en limiter la portée.

  
EXEMPLE 1

  
 <EMI ID=29.1> 

  
(rendement 95,7%) de produit que l'on recristallise trois fois dans le mélange chlorure de méthylène-acétate d'éthyle; F. 191-193,5'C.

  

 <EMI ID=30.1> 
 

  
EXEMPLE 2 

  
 <EMI ID=31.1> 

  
après repos pendant 10 min, il commence. précipiter un solide jaune. On maintient le mélange à la température ambiante pendant 18 h. On élimine le solvant dans un évaporateur rotatif. On dissout le résidu dans 200 ml de méthanol et on alcalinise légèrement (pH 8) par le bicarbonate de sodium. On ajoute 700 ml d'eau et il se

  
forme une huile qui se solidifie il cristallisa encore un solide après repos. On filtre ce solide et on la sèche à l'air pour obtenir 6,9 g (rendement 957.) de produit brut. On dissout le solide dans

  
 <EMI ID=32.1> 

  
Après refroidissement, il se sépare 6,5 (rendement 89%) d'aiguilles jaune pâle; F. 120-121[deg.]C.

  

 <EMI ID=33.1> 


  
EXEMPLE 3 à 71

  
 <EMI ID=34.1> 

  
carboxylate d'éthyle, à partir du. composé de l'exemple 3 et d'acide sulfurique, 

  
 <EMI ID=35.1> 

  
léinecarboxylate d'éthyle, à partir du composé de l'exemple 3 et d'acide phosphorique,

  
 <EMI ID=36.1>   <EMI ID=37.1> 

  
d'éthyles partir du composé de la préparation 1 et de n-butylamine,

  
 <EMI ID=38.1> 

  
carboxylate d'éthyle, à partir du composé de la préparation 1 et de m-toluidine, 

  
 <EMI ID=39.1> 

  
carboxylate d'éthyle monohydraté., a partir du composé de la préparation 1 et de p-toluidine,

  
 <EMI ID=40.1>   <EMI ID=41.1> 

  
mercaptoaniline,

  
24. méthanolate (1:1) du phosphate (1:1) du 4-benzylamino-8-méthoxy-

  
 <EMI ID=42.1> 

  
d'éthyle, a partir du composé de la préparation 1 et de 2,6dichloroaniline,  <EMI ID=43.1> 

  
carboxylate d'éthyle, . partir du composé de la préparation 3 et de o-aniaidine,

  
 <EMI ID=44.1> 

  
carboxylate d'éthyle, à partir du composé de la préparation 14 et de o-toluidine,

  
 <EMI ID=45.1>   <EMI ID=46.1> 

  
boxylate d'éthyle, à partir du composé de la préparation S et de o-toluidine, 

  
 <EMI ID=47.1> 

  
partir du composé de la préparation 6 et d'aniline,  <EMI ID=48.1> 

  
d'éthyle, , partir du composé de la préparation 2 et de 2-chloroaniline,

  
 <EMI ID=49.1> 

  
carboxylate d'éthyle, à partir du compote de la préparation 15 et de l'aniline,

  
 <EMI ID=50.1> 

  
o-toluidine,   <EMI ID=51.1> 

  
aniline.

  
EXEMPLE 72

  
 <EMI ID=52.1> 

  

 <EMI ID=53.1> 


  
EXEMPLE 73

  
 <EMI ID=54.1> 

  

 <EMI ID=55.1> 
 

  
 <EMI ID=56.1> 

  
d'éthyle, à partir du composé de la préparation 1 et de 2-nitroaniline, 

  
 <EMI ID=57.1> 

  
l'éthanol absolu.

  
EXEMPLE 81 

  
 <EMI ID=58.1> 

  
50 ml de 2-propanol anhydre. On agit* la solution et on chauffe au

  
 <EMI ID=59.1> 

  
jette. On évapora le solvant et.on dissout le résidu dans 50 ml d'acide chlorhydrique 2,9 M et on ajoute 100 ml d'eau. On ajuste la

  
 <EMI ID=60.1>  

  
"EMPLI 86 

  
 <EMI ID=61.1> 

  
absolu.

  
EXEMPLE 89

  
 <EMI ID=62.1> 

PHARMACOLOGIE 

  
On a étudié chez les rite et les chiens l'action

  
 <EMI ID=63.1> 

  
l'invention présentent des effets qualitativement semblables dans, un ou plusieurs de ces essaie@ On administre le composé de l'exemple 1 à des rats <EMI ID=64.1> 

  
en solutions, émulsions, suspensions, pilules, tablettes, pastillas,

  
 <EMI ID=65.1> 

  
par- exemple, un solide ou un liquide. A titre d'exemples de supporte solides, on peut citer le lactose, la saccharose, le talc, la gélatine, la gélose, la pectine, la gomme arabique, le stéarate

  
 <EMI ID=66.1> 

  
Bien que de très faibles quantités des -substances actives de l'invention soient efficaces dans le ces d'une thérapie mineure pour l'irritation gastrique ou dans des cas d'administration à des sujets de faible poids corporel, les dotes unitaires contiennent ordinairement une quantité de l'ingrédient actif correspondant à

  
 <EMI ID=67.1>   <EMI ID=68.1> 

  
que l'on obtienne une dote efficace, convenable en rapport avec la forme de dosage utilisée. Les, doses individuelles "actes, ainsi que les doses journalières, sont bien entendu déterminées selon les prin*

  
 <EMI ID=69.1> 

  
d'administration des composée de l'invention. 

  
1. capsules

  

 <EMI ID=70.1> 


  
On mélange et on remplit avec le mélange des capsules de gélatine.

  
2. Tablettes 

  

 <EMI ID=71.1> 


  
 <EMI ID=72.1> 

  
On mélange ensuite/ vigoureusement le produit granulé séché avec la  <EMI ID=73.1> 

  

 <EMI ID=74.1> 


  
Il :et entendu que l'invention n'ait pas limitée aux

  
 <EMI ID=75.1> 

  
tion et que l'homme de l'art peut y apporter diverses modifications et divers changements sans toutefois s'écarter du cadre et de l'esprit de l'invention. 

  
 <EMI ID=76.1> 
 <EMI ID=77.1> 
  <EMI ID=78.1> 
 <EMI ID=79.1> 
  <EMI ID=80.1> 
 <EMI ID=81.1> 
 <EMI ID=82.1>   <EMI ID=83.1> 
 <EMI ID=84.1> 
  <EMI ID=85.1> 

  

 <EMI ID=86.1> 
 

REVENDICATIONS

  
 <EMI ID=87.1> 

  
raie

  

 <EMI ID=88.1> 


  
dans laquelle R. représente un atome d'halogène ou un groupe alkyle

  
 <EMI ID=89.1> 

  
0, 1 ou 2, et leurs sale d'addition d'acides.



  The present invention relates to certain acids and

  
 <EMI ID = 1.1>

  
America No. 3,470,186 and in J. Med. Chem. 1969, 12 (6), pages 1096-
1097.

  
 <EMI ID = 2.1>

  
Compounds useful according to the invention for inhibiting

  
secretion of hydrochloric acid and treat peptic ulcers

  
 <EMI ID = 3.1>

  

 <EMI ID = 4.1>


  
 <EMI ID = 5.1> <EMI ID = 6.1>

  
by food has also been reduced.

  
The subject of the invention is therefore a new method

  
 <EMI ID = 7.1>

  
the invention for various routes of administration.

  
Other objects and advantages of the invention appear

  
 <EMI ID = 8.1>

  
the following equation

  

 <EMI ID = 9.1>


  
 <EMI ID = 10.1>

  
a lower alkyl group.

  
The compounds of formula II are prepared by chlorura-

  
 <EMI ID = 11.1>

  
reaction is as follows

  

 <EMI ID = 12.1>


  
 <EMI ID = 13.1>

  
lower alkyl group.

  
The compounds of formula III are prepared in which

  
 <EMI ID = 14.1>

  
pages 1204-1208. The reaction is represented by the following equation:

  

 <EMI ID = 15.1>


  
 <EMI ID = 16.1>

  
lysis and other esters of the invention can be prepared by usual techniques of re-esterification.

  
 <EMI ID = 17.1>

  
general formula

  

 <EMI ID = 18.1>


  
 <EMI ID = 19.1> <EMI ID = 20.1>

  
laughing, (lower alkyl) lower alkoxy or allyl, and their pharmaceutically acceptable acid addition salts.

  
For example, we found that the effect of hydrochloride

  
 <EMI ID = 21.1>

  
 <EMI ID = 22.1>

  
The synthesis used to prepare the 4-chloro compounds of formula II which are the starting materials used for the preparation of the compounds of formula 1 is described below. Preparation 1

  
 <EMI ID = 23.1>

  
of phosphorus oxychloride until all the solid has dissolved, and then heated to reflux for 2 h. After cooling below 100 ° C., the mixture is concentrated in a rotary evaporator. The residual oil is dissolved in 100 ml of acetone

  
and the solution is poured onto 800 ml of an ice-water mixture. We neutralized

  
 <EMI ID = 24.1>

  
solid successively with 450 ml, 250 ml and 100 ml of methylene chloride. The extracts are combined, washed with water, dried over

  
 <EMI ID = 25.1>

  
of an oil which crystallizes on cooling into a dirty white solid. F. 75-77 * C.

  

 <EMI ID = 26.1>
 

  
The foregoing is a general description of the preparation of the wrongs of the invention. Examples 1 and 2 below illustrate in general the preparation of the esters. The

  
 <EMI ID = 27.1>

  
of acids is illustrated in Examples 72 and 73, where the ester is hydrolyzed to acid. The metal salts of the acids, such as the alkali metal salts, can also be prepared by the usual methods of reaction with an alkali metal base and isolation of such. Examples 85 to 88 further illustrate the conversion of

  
 <EMI ID = 28.1>

  
The following examples illustrate the invention without, however, limiting its scope.

  
EXAMPLE 1

  
 <EMI ID = 29.1>

  
(yield 95.7%) of product which is recrystallized three times from the methylene chloride-ethyl acetate mixture; F. 191-193.5'C.

  

 <EMI ID = 30.1>
 

  
EXAMPLE 2

  
 <EMI ID = 31.1>

  
after resting for 10 min, it begins. precipitate a yellow solid. The mixture is kept at room temperature for 18 h. The solvent is removed in a rotary evaporator. The residue is dissolved in 200 ml of methanol and slightly basified (pH 8) with sodium bicarbonate. 700 ml of water are added and it

  
forms an oil which solidifies it still crystallizes a solid after rest. This solid is filtered and dried in air to obtain 6.9 g (yield 957.) of crude product. We dissolve the solid in

  
 <EMI ID = 32.1>

  
After cooling, it separates 6.5 (89% yield) from pale yellow needles; F. 120-121 [deg.] C.

  

 <EMI ID = 33.1>


  
EXAMPLE 3 to 71

  
 <EMI ID = 34.1>

  
ethyl carboxylate, from. composed of Example 3 and sulfuric acid,

  
 <EMI ID = 35.1>

  
ethyl leinecarboxylate, from the compound of Example 3 and phosphoric acid,

  
 <EMI ID = 36.1> <EMI ID = 37.1>

  
ethyl from the compound of Preparation 1 and n-butylamine,

  
 <EMI ID = 38.1>

  
ethyl carboxylate, from the compound of preparation 1 and m-toluidine,

  
 <EMI ID = 39.1>

  
ethyl carboxylate monohydrate., starting from the compound of preparation 1 and p-toluidine,

  
 <EMI ID = 40.1> <EMI ID = 41.1>

  
mercaptoaniline,

  
24. 4-benzylamino-8-methoxy- (1: 1) phosphate methanolate (1: 1)

  
 <EMI ID = 42.1>

  
ethyl, from the compound of Preparation 1 and 2,6dichloroaniline, <EMI ID = 43.1>

  
ethyl carboxylate,. from the compound of preparation 3 and o-aniaidine,

  
 <EMI ID = 44.1>

  
ethyl carboxylate, from the compound of preparation 14 and o-toluidine,

  
 <EMI ID = 45.1> <EMI ID = 46.1>

  
ethyl boxylate, from the compound of preparation S and o-toluidine,

  
 <EMI ID = 47.1>

  
from the compound of preparation 6 and aniline, <EMI ID = 48.1>

  
ethyl, from the compound of preparation 2 and 2-chloroaniline,

  
 <EMI ID = 49.1>

  
ethyl carboxylate, from the compote of preparation 15 and aniline,

  
 <EMI ID = 50.1>

  
o-toluidine, <EMI ID = 51.1>

  
aniline.

  
EXAMPLE 72

  
 <EMI ID = 52.1>

  

 <EMI ID = 53.1>


  
EXAMPLE 73

  
 <EMI ID = 54.1>

  

 <EMI ID = 55.1>
 

  
 <EMI ID = 56.1>

  
ethyl, from the compound of preparation 1 and 2-nitroaniline,

  
 <EMI ID = 57.1>

  
absolute ethanol.

  
EXAMPLE 81

  
 <EMI ID = 58.1>

  
50 ml of anhydrous 2-propanol. The solution is acted upon and heated to

  
 <EMI ID = 59.1>

  
throw. The solvent is evaporated and the residue is dissolved in 50 ml of 2.9 M hydrochloric acid and 100 ml of water are added. We adjust the

  
 <EMI ID = 60.1>

  
"EMPLI 86

  
 <EMI ID = 61.1>

  
absolute.

  
EXAMPLE 89

  
 <EMI ID = 62.1>

PHARMACOLOGY

  
We studied in rites and dogs the action

  
 <EMI ID = 63.1>

  
the invention exhibit qualitatively similar effects in one or more of these tests. The compound of Example 1 is administered to rats <EMI ID = 64.1>

  
in solutions, emulsions, suspensions, pills, tablets, pastillas,

  
 <EMI ID = 65.1>

  
for example, a solid or a liquid. As examples of solid supports, there may be mentioned lactose, sucrose, talc, gelatin, agar, pectin, gum arabic, stearate

  
 <EMI ID = 66.1>

  
Although very small amounts of the active substances of the invention are effective in the treatment of minor therapy for gastric irritation or in cases of administration to subjects of low body weight, unit dotes usually contain a amount of the active ingredient corresponding to

  
 <EMI ID = 67.1> <EMI ID = 68.1>

  
that we obtain an effective dowry, suitable in relation to the dosage form used. The, individual doses "acts, as well as the daily doses, are of course determined according to the prin *

  
 <EMI ID = 69.1>

  
administration of the compounds of the invention.

  
1. capsules

  

 <EMI ID = 70.1>


  
Mix and fill with the mixture of gelatin capsules.

  
2. Tablets

  

 <EMI ID = 71.1>


  
 <EMI ID = 72.1>

  
The dried granulated product is then vigorously mixed with the <EMI ID = 73.1>

  

 <EMI ID = 74.1>


  
He: and understood that the invention was not limited to

  
 <EMI ID = 75.1>

  
tion and that those skilled in the art can make various modifications and various changes without however departing from the scope and spirit of the invention.

  
 <EMI ID = 76.1>
 <EMI ID = 77.1>
  <EMI ID = 78.1>
 <EMI ID = 79.1>
  <EMI ID = 80.1>
 <EMI ID = 81.1>
 <EMI ID = 82.1> <EMI ID = 83.1>
 <EMI ID = 84.1>
  <EMI ID = 85.1>

  

 <EMI ID = 86.1>
 

CLAIMS

  
 <EMI ID = 87.1>

  
skate

  

 <EMI ID = 88.1>


  
in which R. represents a halogen atom or an alkyl group

  
 <EMI ID = 89.1>

  
0, 1 or 2, and their acid addition rooms.


    

Claims (1)

2 - Composés selon la revendication 1, caractérisée en ce qu'ils répondent à la foranls générale : <EMI ID=90.1> <EMI ID=91.1> <EMI ID=92.1> 2 - Compounds according to claim 1, characterized in that they meet the general foranls: <EMI ID = 90.1> <EMI ID = 91.1> <EMI ID = 92.1> carboxylate d'éthyle ou son chlorhydrate. ethyl carboxylate or its hydrochloride. 8 - Composé selon la revendication 2, caractérisé en ce 8 - Compound according to claim 2, characterized in that <EMI ID=93.1> <EMI ID = 93.1> carboxylate d'éthyle ou son chlorhydrate). ethyl carboxylate or its hydrochloride). <EMI ID=94.1> <EMI ID=95.1> 28 - Forme d'administration de$ compositions "Ion <EMI ID = 94.1> <EMI ID = 95.1> 28 - Form of administration of $ compositions "Ion <EMI ID=96.1> <EMI ID = 96.1> tions aux mélanges stériles pour l'administration parentérale. sterile mixtures for parenteral administration. 29 - Formes d'administration salon la revendication 28, 29 - Forms of administration according to claim 28, <EMI ID=97.1> <EMI ID = 97.1> 500 mg et la dose journalière entre 100 et 1 200 mg pour l'homme adulte. 500 mg and the daily dose between 100 and 1,200 mg for adult men.
BE0/199934A 1979-03-26 1980-03-25 NOVEL 4-AMINO-3-QUINOLEINE-CARBOXYLIC ACIDS AND ESTERS, ESPECIALLY USEFUL AS ANTISECRETORY AND ANTI-ULCER AGENTS BE882414A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2398179A 1979-03-26 1979-03-26

Publications (1)

Publication Number Publication Date
BE882414A true BE882414A (en) 1980-07-16

Family

ID=21818223

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/199934A BE882414A (en) 1979-03-26 1980-03-25 NOVEL 4-AMINO-3-QUINOLEINE-CARBOXYLIC ACIDS AND ESTERS, ESPECIALLY USEFUL AS ANTISECRETORY AND ANTI-ULCER AGENTS

Country Status (5)

Country Link
JP (1) JPS55147222A (en)
KR (1) KR840000768B1 (en)
BE (1) BE882414A (en)
HU (1) HU184253B (en)
ZA (1) ZA801526B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804444D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
WO1991014677A1 (en) * 1990-03-28 1991-10-03 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative, antiulcer drug containing the same, and production of said derivative
FR2862301B1 (en) * 2003-11-17 2007-12-21 Aventis Pharma Sa NEW PROCESS FOR THE PREPARATION OF 3-FLUORINATED QUINOLINES

Also Published As

Publication number Publication date
ZA801526B (en) 1981-08-26
JPS55147222A (en) 1980-11-17
HU184253B (en) 1984-07-30
KR830001899A (en) 1983-05-19
KR840000768B1 (en) 1984-06-08
JPH0227329B2 (en) 1990-06-15

Similar Documents

Publication Publication Date Title
EP0073161B1 (en) Pyridazine derivatives active on the central nerve system
EP0151072B1 (en) Derivatives of methylenediphosphonic acid, process for their preparation and antirheumatic pharmaceutical compositions containing them
EP0643701B1 (en) Benzimidazole-derived compounds, method for preparing same, and therapeutical and cosmetic uses thereof
FR2595695A1 (en) N - ((((2-HYDROXYHYL) PHENYL) (PHENYL) METHYLENE) AMINO-2) ETHYL) ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP0482183A1 (en) Novel histamine h 3?-receptor agonist compounds for therapeutic use, pharmaceutical compositions acting as agonists of said receptor and method of preparation.
EP0063084B1 (en) Phenethanol amine derivatives, their preparation and use in medicine
BE882414A (en) NOVEL 4-AMINO-3-QUINOLEINE-CARBOXYLIC ACIDS AND ESTERS, ESPECIALLY USEFUL AS ANTISECRETORY AND ANTI-ULCER AGENTS
FR2637596A1 (en) METHYL-4 ((ARYL-4-PIPERAZINYL-1) -2-ETHYL) -5 THIAZOLE AND ITS DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENTS CONTAINING THE SAME
CH659469A5 (en) DERIVATIVES OF 4-HYDROXY 3-QUINOLEINE CARBOXYLIC ACID SUBSTITUTED IN 2, THEIR PREPARATION AND THE MEDICINAL PRODUCTS AND COMPOSITIONS CONTAINING THEM.
FR2462444A1 (en) 25-HALOGENO-5-CHOLESTENE-3B, 22-DIOLS AND THEIR USEFUL ESTERS, IN PARTICULAR AS HYPOCHOLESTEROLEMIANTS
CH651294A5 (en) AMINO-2-HALOGENOBENZOYL-3-METHYLPHENYLACETIC ACIDS AND THEIR ESTERS AND SALTS USEFUL AS ANTI-INFLAMMATORY AND ANALGESIC DRUGS.
CA1082716A (en) Process for the preparation of novel 5-thiazole methane amine derivatives
EP0001947B1 (en) 2-amino-thiazoline derivatives, their preparation and their use in pharmaceutical preparations
FR2478094A1 (en) AMMONIO SUBSTITUTED CINNAMYLMORANOLINE DERIVATIVES WITH INHIBITION ACTIVITY OF SUGAR LEVEL IN BLOOD
CA2158663A1 (en) Perhydroisoindole derivatives, their preparation and pharmaceutical compositions containing them
CH641775A5 (en) N- (1-METHYL 2-PYRROLIDINYL METHYL) 2,3-DIMETHOXY 5-METHYLSULFAMOYL BENZAMIDE AND DERIVATIVES THEREOF, PROCESS FOR PREPARING THE SAME AND COMPOSITION FOR THE CONTAINER.
FR2504136A1 (en) (2,6-DIMETHOXY-4-HYDROXYPHENYL) - (3-PIPERIDINOPROPYL) -CETONE AND ITS ADDITION SALTS, THERAPEUTIC USE AND PREPARATION METHOD
CA1068270A (en) 2,4-diamino-5-bromo-6-chloro pyrimidines, process of making them and pharmaceutical applications
DE68907893T2 (en) NEW 1,3,4, -THIADIAZOLE DERIVATIVES AND ANTIGULAR DRUGS CONTAINING THEM.
EP0161235A2 (en) Thienopyridinone derivatives, process for their preparation and pharmaceutical compositions containing them
FR2480602A1 (en) HEXAHYDRO-PYRIMIDO (1,2-A) AZEPINES 3-SUBSTITUTED AS DRUGS
BE862346R (en) NEW DERIVATIVES OF PENICILLANIC ACIDS AND THEIR THERAPEUTIC USE
FR2556592A1 (en) Pharmaceutical compositions containing camphormethylidenecinnamic acid derivatives
CH648295A5 (en) 2-AMINO-3- (ALKYLTHIOBENZYL) -PHENYLACETIC ACIDS AND THEIR DERIVATIVES.
DE2755345A1 (en) 2-OXO-PHENYLBUTTERIC ACID DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: A.H. ROBINS CY INC.

Effective date: 19920331